STAT3 and rhabdomyosarcoma: LY5, a small molecule inhibitor that antagonizes constitutive and inducible STAT3 activation, was shown to inhibit tumor cell migration and angiogenesis and to induce apoptosis in medulloblastoma, osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma cells [36–39].